Advertisement

International Ophthalmology

, Volume 39, Issue 2, pp 341–345 | Cite as

Mitomycin C 0.02 and 0.002% efficacy in preventing haze after photorefractive keratectomy

  • L. M. CoelhoEmail author
  • R. O. Sieiro
Original Paper
  • 96 Downloads

Abstract

Purpose

To compare MMC 0.002% efficacy in preventing haze after PRK in relation to MMC 0.02%.

Patients and methods

We conducted a prospective study with patients with myopia or myopic astigmatism undergoing PRK in the same conditions. After PRK, MMC was applied for 30 s in a concentration of 0.02% on the right eye (group 1) and 0.002% on the left eye (group 2). Age, gender, spherical equivalent and haze intensity (1, 3, 6 and 12 months postoperatively) were assessed. Haze was quantified at biomicroscopy (0–4 +). P < 0.05 was considered statistical significant.

Results

We evaluated 130 patients, 77 women and 53 men, with a mean age of 30.2 ± 9 years. The spherical equivalent was − 3.66 D in the group 1 and − 3.77 D in the group 2. In the 1st month after PRK, incidence of haze was 13.9% eyes in group 1 and 14.6% in group 2. In the 3rd month, incidence of haze was 50.0% eyes in group 1 and 48.5% in group 2 which presented with 3 +/4 + traces of haze. In the 12th month, incidence of haze was 7.7% eyes in group 1 and 5.4% in group 2. There was no correlation between haze and age (p = 0.279/0.333), gender (p = 0.345/0.367) or spherical equivalent (p = 0.100/0.054) in groups 1 and 2, respectively. There was no difference in haze between groups 1 and 2 (p = 0.56).

Conclusion

MMC 0.002% was effective in preventing haze after PRK. As MMC long-term safety has not been proved, we suggest its use in a lower concentration, in order to prevent potential complications.

Keywords

Refractive surgical procedures Photorefractive keratectomy PRK complications Corneal haze Mitomycin C 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Santhiago MR, Netto MV, Wilson SE (2012) Mitomycin C: biological effects and use in refractive surgery. Cornea 31(3):311–321CrossRefGoogle Scholar
  2. 2.
    Netto MV et al (2006) Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg 22:562–574CrossRefGoogle Scholar
  3. 3.
    Naderi M, Ahmadi M, Jadidi K, Alishiri A, Rafizadeh P (2010) Comparison of standard and low dose mitomycin C in the prevention of corneal haze following photorefractive keratectomy. Iran J Ophthalmol 22(3):13–16Google Scholar
  4. 4.
    Teus MA, Benito-Llopis L, Alió JL (2009) Mitomycin C in corneal refractive surgery. Surv Ophthalmol 54:487–502CrossRefGoogle Scholar
  5. 5.
    Netto MV, Mohan RR, Sinha S et al (2006) Stromal haze, myofibroblasts, and surface irregularity after PRK. Exp Eye Res 82:788–797CrossRefGoogle Scholar
  6. 6.
    Diakonis VF et al (2014) Contralateral-eye study of surface refractive treatments: clinical and confocal microscopy evaluation. J Cataract Refract Surg 40:224–231CrossRefGoogle Scholar
  7. 7.
    Lacayo GO III, Majmudar PA (2005) How and when to use mitomycin-C in refractive surgery. Curr Opin Ophthalmol 16:256–259CrossRefGoogle Scholar
  8. 8.
    Thornton I, Puri A, Xu M, Krueger RR (2007) Low-dose mitomycin C as a prophylaxis for corneal haze in myopic surface ablation. Am J Ophthalmol 144:673–681CrossRefGoogle Scholar
  9. 9.
    Majmudar PA et al (2000) Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology 107:89–94CrossRefGoogle Scholar
  10. 10.
    Sia RK, Ryan DS, Edwards JD, Stutzman RD, Bower KS (2014) The U.S. army surface ablation study: comparison of PRK, MMC-PRK, and LASEK in moderate to high myopia. J Refract Surg 30(4):256–264CrossRefGoogle Scholar
  11. 11.
    Virasch VV, Majmudar PA, Epstein RJ et al (2010) Reduced application time for prophylactic mitomycin C in photorefractive keratectomy. Ophthalmology 117:885–889CrossRefGoogle Scholar
  12. 12.
    Hofmeister EM, Bishop FM, Kaupp SE, Schallhorn SC (2013) Randomized dose-response analysis of mitomycin-C to prevent haze after photorefractive keratectomy for high myopia. J Cataract Refract Surg 39:1358–1365CrossRefGoogle Scholar
  13. 13.
    Gambato C, Ghirlando A, Moretto E, Busato F, Midena E (2005) Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology 112:208–219CrossRefGoogle Scholar
  14. 14.
    Crawford C et al (2013) Systemic absorption of mitomycin-C when used in refractive surgery. J Cataract Refract Surg 39:193–196CrossRefGoogle Scholar
  15. 15.
    Song JS, Kim JH, Yang M, Sul D, Kim HM (2007) Mitomycin C concentration in cornea and aqueous humor and apoptosis in the stroma after topical mitomycin-C application. Effects of mitomycin-C application time and concentration. Cornea 26:461–467CrossRefGoogle Scholar
  16. 16.
    Stojanovic A, Nitter TA (2001) Correlation between ultraviolet radiation level and the incidence of late-onset corneal haze after photorefractive keratectomy. J Cataract Refract Surg 27:404–410CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Instituto de Olhos de Belo Horizonte (IOBH)Universidade Federal de Minas Gerais (UFMG)Belo HorizonteBrazil
  2. 2.Faculdade de Ciências Médicas de Minas Gerais (FCMMG)Belo HorizonteBrazil

Personalised recommendations